SCHEMBL21615071

SCHEMBL21615071

COC(=O)c1ccc(C)c(-n2cc(-c3cncn3C)nn2)c1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 13/20 0.66
BRAF P15056 6/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21611777 0.88 GPR142 (0.66) GPR142BRAF
SCHEMBL29084551 0.81 CYP19A1 (0.53) GPR142BRAFALDH1A1
SCHEMBL29625998 0.81 CYP19A1 (0.53) GPR142BRAFALDH1A1
SCHEMBL21615099 0.80 GPR142 (1.00) GPR142BRAF
SCHEMBL21615098 0.79 GPR142 (1.00) GPR142BRAF
SCHEMBL21615154 0.77 GPR142 (1.00) GPR142BRAF
SCHEMBL4037558 0.76 GPR142 (0.57) GPR142BRAF
SCHEMBL1404644 0.75 KDM4E (0.47) GPR142ALDH1A1
SCHEMBL21615090 0.75 GPR142 (1.00) GPR142
SCHEMBL4017487 0.72 MMP2 (0.48) GPR142

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3817811-B1 TRIAZOLE BENZAMIDE DERIVATIVES AS GPR142 AGONISTS BOEHRINGER INGELHEIM INT (DE) 2024-04-03 EP disclosed
CN-112368049-B Triazole benzamide derivatives as GPR142 agonists 勃林格殷格翰国际有限公司 2024-03-29 CN disclosed
US-11179371-B2 Triazole benzamide derivatives as GPR142 agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-11-23 US disclosed
CN-112368049-A Triazole benzamide derivatives as GPR142 agonists 勃林格殷格翰国际有限公司 2021-02-12 CN disclosed
WO-2020007729-A1 TRIAZOLE BENZAMIDE DERIVATIVES AS GPR142 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11179371-B2 Triazole benzamide derivatives as GPR142 agonists GPR119, GPR142, GPR65 GPR142 2/4885BRAF 3861/4885ALDH1A1 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.